Cardiovascular Disease Prevention: Current Knowledge, Future Directions

Similar documents
Cardiovascular Risk Assessment and Management Making a Difference

Environmental. Vascular / Tissue. Metabolics

Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden

The Metabolic Syndrome: Is It A Valid Concept? YES

Diabetes Mellitus: A Cardiovascular Disease

Using Cardiovascular Risk to Guide Antihypertensive Treatment Implications For The Pre-elderly and Elderly

Vascular Diseases. Overview: Selected Slides

Total risk management of Cardiovascular diseases Nobuhiro Yamada

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials

Know Your Number Aggregate Report Single Analysis Compared to National Averages

Dyslipidemia in women: Who should be treated and how?

Northwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient?

The Clinical Unmet need in the patient with Diabetes and ACS

Risk Factors for Heart Disease

ATP IV: Predicting Guideline Updates

EuroPrevent 2010 Fatal versus total events in risk assessment models

well-targeted primary prevention of cardiovascular disease: an underused high-value intervention?

Current Cholesterol Guidelines and Treatment of Residual Risk COPYRIGHT. J. Peter Oettgen, MD

Dyslipidemia: Lots of Good Evidence, Less Good Interpretation.

There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?

Key causes of preventable deaths in New Zealand In a population of 10,000 New Zealanders, every year there will be about:

Preventive Cardiology Scientific evidence

Managing HTN in the Elderly: How Low to Go

Genetic and biochemical characteristics of patients with hyperlipidemia who require LDL apheresis

Dyslipidaemia. Is there any new information? Dr. A.R.M. Saifuddin Ekram

LDL cholesterol and cardiovascular outcomes?

The Heart of a Woman. Karen E. Friday, M.D. Associate Professor of Medicine Section of Endocrinology Louisiana State University School of Medicine

Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway

9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?

CONTRIBUTING FACTORS FOR STROKE:

No relevant financial relationships

Prevenzione cardiovascolare e cambiamento degli stili di vita. Gian Franco Gensini

The Diabetes Link to Heart Disease

Placebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES

Contemporary management of Dyslipidemia

Is Lower Better for LDL or is there a Sweet Spot

The Cardiovascular Institute Mount Sinai School of Medicine, New York

Objectives. Describe results and implications of recent landmark hypertension trials

4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?

YOUNG ADULT MEN AND MIDDLEaged

Cardiovascular Complications of Diabetes

Management of Lipid Disorders and Hypertension: Implications of the New Guidelines

Health Benefits of Lowering Sodium Intake in the US

ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future

Heart Disease Genesis

The target blood pressure in patients with diabetes is <130 mm Hg

CVD Prevention, Who to Consider

CVD risk assessment using risk scores in primary and secondary prevention

Reducing CVD globally through combination approaches to prevention: the polypill. Salim Yusuf

Heart Disease and Stroke Statistics 2010 Update. 2009, American Heart Association. All rights reserved.

ALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic

Threshold Level or Not for Low-Density Lipoprotein Cholesterol

Update on Current Trends in Hypertension Management

Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic

HYPERTENSION GUIDELINES WHERE ARE WE IN 2014

Treating Hypertension in 2018: What Makes the Most Sense Today?

Placebo-Controlled Statin Trials

Prevention of Heart Disease: The New Guidelines

40% minimum reduction from

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

ATP III (Adult Treatment Panel III) CLASSIFICATION C IN ADULTS

Disclosures. Prevention of Heart Disease: The New Guidelines. Summary of Talk. Four guidelines. No relevant disclosures.

Antihypertensive Trial Design ALLHAT

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials

Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center

Update on CVD and Microvascular Complications in T2D

The Art of Cardiovascular Risk Assessment

Lipid Management 2013 Statin Benefit Groups

Blood Pressure Acre Surgery Diviash Thakrar

Using the New Hypertension Guidelines

Disclosures. Background 1 What is Known MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES. Background 2 What is Not Known 10/2/2017

Familial hypercholesterolaemia

Treatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center

Safety of Anacetrapib in Patients with or

Tailored Statin Treatment for Type 2 Diabetes. Han, Ki Hoon Asan Medical Center University of Ulsan

Supplementary Online Content

HDL-C. J Jpn Coll Angiol, 2008, 48: NIPPON DATA80, MEGA study, JELIS, dyslipidemia, risk assessment chart

Placebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN

PCSK9 Inhibitors and Modulators

Myths, Heart Disease and the Latino Population. Maria T. Vivaldi MD MGH Women s Heart Health Program. Hispanics constitute 16.3 % of US population!

A Naturally Randomized Trial Comparing the Effect of Genetic Variants that Mimic CETP Inhibitors and Statins on the Risk of Cardiovascular Disease.

Heart Age and Cardiovascular Risk

Preventing heart disease by controlling hypertension: Impact of hypertensive subtype, stage, age, and sex

Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies

CVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic

Placebo-Controlled Statin Trials Prevention Of CVD in Women"

Practical Diabetes. Nic Crook. (and don t use so many charts) Kuirau Specialists 1239 Ranolf Street Rotorua. Rotorua Hospital Private Bag 3023 Rotorua

Sugar-Loaded Beverages and the Impact on Cardiovascular Health. Christina M. Shay, PhD, MA

Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both

How to Reduce Residual Risk in Primary Prevention

Biases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University

Impact of Lifestyle Modification to Reduce Cardiovascular Disease Event Risk of High Risk Patients with Low Levels of HDL C

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION

10/8/2015. MN Nursing Conference October 7th, 2015 Michael Miedema, MD MPH. None

Aggressive Lipid Management for Diabetes

Macrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?

Joslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia

Identification of subjects at high risk for cardiovascular disease

Approach to Dyslipidemia among diabetic patients

Ischemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010

Transcription:

Cardiovascular Disease Prevention: Current Knowledge, Future Directions Daniel Levy, MD Director, Framingham Heart Study Professor of Medicine, Boston University School of Medicine Editor-in-Chief, Journal of the American Society of Hypertension American College of Osteopathic Internists October 18, 2018

Disclosure of Relationships The views and opinions expressed in this presentation are those of the speaker and not necessarily those of the NIH or HHS No relationships with industry

Leading Causes of Death in the US Year 1900 1. Pneumonia/influenza 2. Tuberculosis 3. Diarrhea Life expectancy 48 (m) 51 (f) Today 1. Heart disease 2. Cancer 3. Stroke Life expectancy 75 (m) 80 (f) Source: www.cdc.gov/nchs/data/hestat/preliminarydeaths04_tables.pdf

Naïve Beliefs About Healthy Lifestyles

Cardiovascular Disease Prevention: Current Knowledge, Future Directions Magnitude of the problem Traditional risk factors Emerging risk factors Genetic risk Future directions

The Big Five

Risk of CHD Death According to SBP and DBP in MRFIT 4 3 Systolic Diastolic Relative Risk 2 1 Decile 0 Systolic BP (mm Hg) Diastolic BP (mm Hg) 1 2 3 4 5 6 7 8 9 10 (lowest 10%) (highest 10%) <112 <71 112-71- 118-76- 121-79- 125-81- 129-84- 132-86- 137-89- 142-92- 151 98 Data from Stamler J, Stamler R, Neaton JD. Arch Intern Med 1993; 153: 598-615.

Risk of Stroke Death According to SBP and DBP in MRFIT Relative Risk Decile 9 8 7 6 5 4 3 2 1 0 Systolic BP (mm Hg) Diastolic BP (mm Hg) Systolic Diastolic 1 2 3 4 5 6 7 8 9 10 (lowest 10%) (highest 10%) <112 <71 112-71- 118-76- 121-79- 125-81- 129-84- 132-86- 137-89- 142-92- >151 >98 Data from Stamler J, Stamler R, Neaton JD. Arch Intern Med 1993; 153: 598-615.

CHD Mortality: Prospective Studies Collaboration IHD Mortality (floating absolute risk and 95% CI) 256 128 64 32 16 8 4 2 1 0 120 140 160 180 Usual Systolic Blood Pressure (mm Hg) 80-89 years 70-79 years 60-69 years 50-59 years 40-49 years 256 128 Prospective Studies Collaboration. Lancet. 2002;360:1903-1913. 64 32 16 8 4 2 1 0 70 80 90 100 110 Usual Diastolic Blood Pressure (mm Hg) 80-89 years 70-79 years 60-69 years 50-59 years 40-49 years

Stroke Mortality: Prospective Studies Collaboration Stroke Mortality (floating absolute risk and 95% CI) 256 128 64 32 16 8 4 2 1 0 120 140 160 180 Usual Systolic Blood Pressure (mm Hg) 80-89 years 70-79 years 60-69 years 50-59 years 256 128 Prospective Studies Collaboration. Lancet. 2002;360:1903-1913. 64 32 16 8 4 2 1 0 70 80 90 100 110 Usual Diastolic Blood Pressure (mm Hg) 80-89 years 70-79 years 60-69 years 50-59 years

Hypertension Awareness, Treatment, and Control among Adults in the US NHANES (1999 2006, 2007 2014)

Prevalence of Hypertension Among Adults in the US NHANES 2011 2014

Trends in Prevalence of Hypertension among Adults in the US NHANES 1988 1994, 1999 2006, and 2007 2014

Risk of Death from CHD: In 356,222 Men in the MRFIT Study 6 Year Rate per 1000 12 10 8 6 4 2 0 3 4 <182 182-202 203-220 221-244 >244 Cholesterol Level (mg/dl) Stamler et al. JAMA 1986;256:2823 6 7 11

Risk of Death from Coronary Heart Disease: In 356,222 Men in the MRFIT Study Stamler et al. JAMA 1986;256:2823

Cholesterol and CHD: Seven Countries Study CHD mortality rates (%) 30 25 20 15 10 Northern Europe United States Southern Europe, Inland Southern Europe, Mediterranean Siberia Japan 5 0 100 125 150 175 200 225 250 275 300 325 350 (2.60) (3.25) (3.90) (4.50) (5.15) (5.80) (6.45) (7.10) (7.75) (8.40) (9.05) Verschuren WMM et al. JAMA. 1995;274:131-136. TC mg/dl (mmol/l)

Prevalence of Elevated Cholesterol in Adults in the US National Health and Nutrition Examination Survey (2011 2014)

Trends in Prevalence of Elevated Cholesterol Levels Among Adolescents Age 12-19 in the US NHANES 1988 1994, 1999 2006, and 2007 2014

Trends in Mean Cholesterol Levels in Adults in the US NHANES 1988 1994, 1999 2006, and 2007 2014

Trends in Elevated Cholesterol Levels in Adults in the US NHANES 2011 2012 and 2013 2014

Prevalence of Cigarette Smoking NHIS, 2003 2015; NSDUH, 2003 2015

Prevalence f Diabetes and Pre-Diabetes Among Adults in the US DM: FBG >125 mg/dl Pre-DM: FBG 100-125 Centers for Disease Control and Prevention, National Diabetes Statistics Report, 2014

Trends in Prevalence of Diabetes among Adults in the US NHANES 1988 1994 and 2011 2014

Diabetes Awareness, Treatment, and Control among Adults in the US NHANES 2011 2014

Prevalence of Overweight and Obesity National Health and Nutrition Examination Survey (NHANES) 2011 to 2014

Prevalence of Obesity in Children and Adolescents National Center for Health Statistics

Prevalence of Obesity in Adults NHANES 2011 2014

Trends in Obesity National Center for Health Statistics 19

Prevalence of Obesity in Adults BRFSS, 2015

Prevalence of Obesity in Adults Whites Blacks BRFSS, 2015

Ideal Health Life s healthy 7 Risk factors Lifestyle factors

Ideal Health

Incidence of CVD by the number of ideal health factors Folsom et al. JACC 2011;57:1690

Prevalence of poor, intermediate, and ideal cardiovascular health among US children aged 12-19 years National Center for Health Statistics, NHANES 2013 to 2014

Prevalence of poor, intermediate, and ideal cardiovascular health among US adults National Center for Health Statistics, NHANES 2013 to 2014

Completion of Draft Sequence of the Human Genome June 2000 I would be willing to make a prediction that within 10 years, we will have the potential of offering any of you the opportunity to find out what particular genetic conditions you may be at increased risk for, based upon the discovery of genes involved in common illnesses like diabetes, hypertension, heart disease, and so on. Francis Collins, June 26, 2000

Best Career Opportunities 1967 2015 PRECISION MEDICINE!

Precision Medicine Tonight, I'm launching a new Precision Medicine Initiative to bring us closer to curing diseases like cancer and diabetes and to give all of us access to the personalized information we need to keep ourselves and our families healthier. President Obama, State of the Union Address, January 20, 2015

Polymorphisms in 9 Lipid Genes Predict Lipid Levels LDL APOB APOE HMGCR LDLR PCSK9 HDL ABCA1 CETP LIPC LPL Kathiresan et al. N Engl J Med March 20, 2008

Polymorphisms in 9 Lipid Genes Predict Lipid Levels LDL P=2x10-18 HDL P=3x10-24 Kathiresan et al. N Engl J Med March 20, 2008

Polymorphisms in 9 Lipid Genes Predict Risk of CVD Kathiresan et al. N Engl J Med March 20, 2008

Genetically Driven Drug Discovery

PCSK9 Mutations and CHD

Using Genetics to Determine Risk

A Genetic Risk Score for Coronary Artery Disease

Performance of Genetic Risk Scores for Other Diseases A-Fib T2D IBD Breast Cancer

Performance of Genetic Risk Scores for 5 Diseases